201 related articles for article (PubMed ID: 6708049)
21. Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies.
Sonawat HM; Leibfritz D; Engel J; Hilgard P
Biochim Biophys Acta; 1990 Apr; 1052(1):36-41. PubMed ID: 2322593
[TBL] [Abstract][Full Text] [Related]
22. Base-catalyzed hydrolysis of 4-hydroperoxycyclophosphamide: evidence for iminocyclophosphamide as an intermediate.
Borch RF; Getman KM
J Med Chem; 1984 Apr; 27(4):485-90. PubMed ID: 6708050
[TBL] [Abstract][Full Text] [Related]
23. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
24. 31P NMR studies of the kinetics of bisalkylation by isophosphoramide mustard: comparisons with phosphoramide mustard.
Boal JH; Williamson M; Boyd VL; Ludeman SM; Egan W
J Med Chem; 1989 Aug; 32(8):1768-73. PubMed ID: 2754703
[TBL] [Abstract][Full Text] [Related]
25. Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.
Boal JH; Ludeman SM; Ho CK; Engel J; Niemeyer U
Arzneimittelforschung; 1994 Jan; 44(1):84-93. PubMed ID: 8135883
[TBL] [Abstract][Full Text] [Related]
26. Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood.
Anderson LW; Ludeman SM; Colvin OM; Grochow LB; Strong JM
J Chromatogr B Biomed Appl; 1995 May; 667(2):247-57. PubMed ID: 7663697
[TBL] [Abstract][Full Text] [Related]
27. Aldophosphamide: synthesis, characterization, and comparison with "Hohorst's aldophosphamide".
Struck RF
Cancer Treat Rep; 1976 Apr; 60(4):317-9. PubMed ID: 1277207
[TBL] [Abstract][Full Text] [Related]
28. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione.
Dirven HA; van Ommen B; van Bladeren PJ
Cancer Res; 1994 Dec; 54(23):6215-20. PubMed ID: 7954469
[TBL] [Abstract][Full Text] [Related]
29. Inhibition by cyanamide of 4-hydroxycyclophosphamide/aldophosphamide oxidation to carboxyphosphamide.
Domeyer BE; Sladek NE
Biochem Pharmacol; 1981 Aug; 30(15):2065-73. PubMed ID: 7295327
[No Abstract] [Full Text] [Related]
30. Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.
Niemeyer U; Engel J; Scheffler G; Molge K; Sauerbier D; Weigert W
Invest New Drugs; 1984; 2(2):133-9. PubMed ID: 6469506
[TBL] [Abstract][Full Text] [Related]
31. Proton magnetic resonance studies of the decomposition of 4-hydroxycyclophosphamide, a microsomal metabolite of cyclophosphamide.
Valente EJ; Chan KK; Servis KL
Pharm Res; 1984 Mar; 1(2):89-92. PubMed ID: 24277218
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of reactive metabolite-analogues of cyclophosphamide for comparisons of NMR kinetic parameters and anticancer screening data.
Ludeman SM; Boyd VL; Regan JB; Gallo KA; Zon G; Ishii K
Drugs Exp Clin Res; 1986; 12(6-7):527-32. PubMed ID: 3743371
[TBL] [Abstract][Full Text] [Related]
33. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
34. [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].
Wagner T; Heydrich D; Voelcker G; Hohorst HJ
J Cancer Res Clin Oncol; 1980 Jan; 96(1):79-92. PubMed ID: 7358774
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
36. Effects of N-substitution on the activation mechanisms of 4-hydroxycyclophosphamide analogues.
Kwon CH; Borch RF
J Med Chem; 1989 Jul; 32(7):1491-6. PubMed ID: 2738883
[TBL] [Abstract][Full Text] [Related]
37. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers.
Low JE; Borch RF; Sladek NE
Cancer Res; 1983 Dec; 43(12 Pt 1):5815-20. PubMed ID: 6640533
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)].
Voelcker G; Haeglsperger R
Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370
[TBL] [Abstract][Full Text] [Related]
39. Analysis of 4-hydroxycyclophosphamide by gas chromatography-mass spectrometry in plasma.
Hong PS; Chan KK
J Chromatogr; 1989 Oct; 495():131-8. PubMed ID: 2613798
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
Maki PA; Sladek NE
Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
